Revenio Group Corporation: Increased number of shares entered into trade register

Revenio Group Corporation, Stock Exchange Release, August 19, 2020 at 9.00

INCREASED NUMBER OF SHARES ENTERED INTO TRADE REGISTER

Total of 321 new share subscriptions based on the company’s 2015C stock options approved by the Board of Directors of Revenio Group Corporation on August 5, 2020, have been entered into the trade register today. The share subscription price under 2015C option rights was 12.48 EUR per share. The subscription period for 2015C options is May 31, 2019 – May 31, 2021.

After these subscriptions, the number of Revenio Group Corporation's shares and votes will rise to 26,627,557. The subscription price of the shares is recorded in their entirety in the reserve for invested unrestricted equity.

Revenio Group Corporation has applied for the listing of its new shares on the Nasdaq Helsinki in the same series as the company's existing shares. According to the current estimate, the new shares will be listed on August 20, 2020.

Revenio Group Corporation
Board of Directors

For further information, please contact:
Jouni Toijala, CEO, tel.  +358 50 484 0085
jouni.toijala@revenio.fi
www.revenio.fi

DISTRIBUTION:

Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA)
Principal media

www.revenio.fi 

Revenio Group in brief

Revenio is a health tech group operating on the international market and a global leader in ophthalmological devices. Revenio Group’s ophthalmic diagnostic solutions include intraocular pressure measurement devices under the Icare brand and retinal imaging devices. The main tool for the detection and diagnosis of glaucoma and its monitoring during treatment are intraocular pressure measurement (tonometry), retinal imaging, and visual field tests (perimetry).

The Revenio Group comprises, Icare Finland Oy, Icare USA Inc., Revenio Italy S.R.L, CenterVue SpA, Revenio Research Oy, Done Medical Oy and Oscare Medical Oy.

The common denominators of Revenio's business operations include patient-led screening, follow-up and the global need to make cost savings in health care via preventive measures. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The goal is to create better quality of life through health technology solutions that enable more efficient diagnostics. The focus of the Group is on the early detection of glaucoma, diabetic retinopathy and macular degeneration, and the monitoring of these during the treatment process. Revenio Research focuses on the commercialization of systems that support the diagnosis of skin cancer and asthma and planning their treatment.

In 2019, the Group's net sales totalled EUR 49.5 million, with its net operating profit standing at 25.5%. Revenio Group Corporation is listed on Nasdaq Helsinki.